Shanghai Rendu Biotechnology Co

Shanghai Rendu Biotechnology Co Net Tangible Assets

The Net Tangible Assets of Shanghai Rendu Biotechnology Co (688193.SS) as of Nov 3, 2026 is 913.91 M CNY. In the previous year, Net Tangible Assets was 911.47 M CNY — a change of 0.27% (higher).

Net Tangible Assets

913.91 MCNY

YoY

0.27%

Last updated:

Net Tangible Assets of Shanghai Rendu Biotechnology Co is 2025 913.91 M CNY. Net Tangible Assets of Shanghai Rendu Biotechnology Co was 2024 911.47 M CNY. It decreases by 0.27% higher compared to the previous year.

The Shanghai Rendu Biotechnology Co Net Tangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Tangible Assets
Date
Net Tangible Assets
Jan 1, 2018
142.85 M CNY
Jan 1, 2019
150.55 M CNY
Jan 1, 2020
214.51 M CNY
Jan 1, 2021
287.15 M CNY
Jan 1, 2022
960.72 M CNY
Jan 1, 2023
962.29 M CNY
Jan 1, 2024
911.47 M CNY
Jan 1, 2025
913.91 M CNY
The Shanghai Rendu Biotechnology Co Net Tangible Assets history
YEARNet Tangible AssetsYoY
913.91 MCNY+0.27%
911.47 MCNY-5.28%
962.29 MCNY+0.16%
960.72 MCNY+234.57%
287.15 MCNY+33.86%
214.51 MCNY+42.49%
150.55 MCNY+5.39%
142.85 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Shanghai Rendu Biotechnology Co Stock analysis

What does Shanghai Rendu Biotechnology Co do? Shanghai Rendu Biotechnology Co., Ltd. generates revenue through the sale of molecular diagnostic tests and medical instruments. The company develops diagnostic reagents using RNA isothermal amplification technology, including respiration series, reproduction series, enterovirus series, and blood-borne diseases series. These products are sold domestically within China, targeting healthcare providers and laboratories that require rapid and accurate diagnostic solutions. The firm's focus on domestic market sales ensures consistent demand for its specialized reagents and instruments. The company's product portfolio includes multiple series of diagnostic reagents designed for specific health conditions, such as respiratory and reproductive health. Medical instruments are also manufactured and sold alongside these reagents. Domestic sales within China form the primary revenue stream, with no mention of international markets or additional product lines. The firm's technology and product offerings cater to the needs of medical professionals seeking efficient diagnostic tools. Shanghai Rendu Biotechnology's business model relies on the domestic market for all product sales, with no indication of export or international partnerships. The company's workforce of 528 full-time employees supports the development, manufacturing, and sales of its diagnostic reagents and instruments. Revenue is derived solely from the sale of these products within China, without any reference to third-party collaborations or additional services. Shanghai Rendu Biotechnology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Shanghai Rendu Biotechnology Co stock

Net Tangible Assets of Shanghai Rendu Biotechnology Co is 913.91 M CNY in 2025.

Net Tangible Assets of Shanghai Rendu Biotechnology Co changed from 911.47 M CNY to 913.91 M CNY, representing a 0.27% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Tangible Assets Shanghai Rendu Biotechnology Co since 2006 – with annual values, charts, and detailed analysis.

Net tangible assets equal total assets minus intangible assets, goodwill, and liabilities. They represent the physical asset backing of a company.

Net Tangible Assets's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Tangible Assets's Shanghai Rendu Biotechnology Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Shanghai Rendu Biotechnology Co

All Key Metrics — Shanghai Rendu Biotechnology Co